利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.022 秒)

    METHOD OF MODULATING THE EFFICIENCY OF TRANSLATION TERMINATION AND DEGRADATION OF ABERRANT MRNA INVOLVING A SURVEILLANCE COMPLEX COMPRISING HUMAN UPF1P, EUCARYOTIC RELEASE FACTOR 1 AND EUCARYOTIC RELEASE FACTOR 3
    4.
    发明授权
    METHOD OF MODULATING THE EFFICIENCY OF TRANSLATION TERMINATION AND DEGRADATION OF ABERRANT MRNA INVOLVING A SURVEILLANCE COMPLEX COMPRISING HUMAN UPF1P, EUCARYOTIC RELEASE FACTOR 1 AND EUCARYOTIC RELEASE FACTOR 3 有权
    调节转录终止和涉及包含人UPF1P，真菌释放因子1和释放因子3的监测复合物的转录终止和降解效率的方法

    公开(公告)号：US06486305B1

    公开(公告)日：2002-11-26

    申请号：US09639987

    申请日：2000-08-16

    申请人： Stuart Peltz ,  Kevin Czaplinski ,  Youmin Weng

    发明人： Stuart Peltz ,  Kevin Czaplinski ,  Youmin Weng

    IPC分类号： A23J100

    CPC分类号： C07K14/4703

    摘要： This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex. This invention provides a purified complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. Further, this invention provides an expression vector which comprises a nucleic acid encoding a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) operably linked to a regulatory element. This invention provides an antibody which binds to the complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. This invention provides an agent which inhibits or modulates the binding of human Upf1p to eRF1 or eRF3 The agent may inhibit or facilitate the binding of human Upf1p to eRF1 or eRF3.

    摘要翻译： 本发明提供了调节mRNA的翻译终止效率和/或促进不良转录物降解的方法。 此外，本发明提供了筛选涉及增强翻译终止的药物活性的方法以及鉴定涉及蛋白质复合物缺陷的疾病状态的方法。本发明提供了一种纯化的复合物，其包含一定量的人Upf1p蛋白，一种肽基真核 释放因子1（eRF1）和有效调节翻译终止的肽基真核生物释放因子3（eRF3）。 此外，本发明提供了一种表达载体，其包含编码人Upf1p蛋白的核酸，与调控元件可操作地连接的肽基真核生物释放因子1（eRF1）和肽基真核生物释放因子3（eRF3）。本发明提供抗体 其结合复合物，其包含一定量的人Upf1p蛋白，肽基真核生物释放因子1（eRF1）和有效调节翻译终止的肽基真核生物释放因子3（eRF3）。 本发明提供抑制或调节人Upf1p与eRF1或eRF3的结合的试剂。该试剂可抑制或促进人Upf1p与eRF1或eRF3的结合。

    Method of identifying an antiviral agent
    7.
    发明申请
    Method of identifying an antiviral agent 审中-公开
    识别抗病毒剂的方法

    公开(公告)号：US20070059684A1

    公开(公告)日：2007-03-15

    申请号：US11406714

    申请日：2006-04-19

    申请人： Stuart Peltz ,  Jonathan Dinman ,  Ying Cui

    发明人： Stuart Peltz ,  Jonathan Dinman ,  Ying Cui

    IPC分类号： C12Q1/70 ,  C12Q1/68 ,  C12N1/18 ,  C12N15/74

    CPC分类号： C07K14/4702 ,  A61K31/513 ,  A61K38/1709 ,  G01N33/92

    摘要： A method of identifying an antiviral agent effective against viruses, which utilize −1 programmed ribosomal frameshifting is provided. The method includes providing cells harboring a −1 frame plasmid including a translation start site followed by a −1 ribosomal frameshifting signal followed by a reporter gene which is in a −1 frame relative to the translation start site. The method further includes contacting the cells with a test agent; and measuring the activity of the reporter gene in the presence of the test agent, wherein the reporter gene activity is dependent on −1 ribosomal frameshifting.

    摘要翻译： 提供了鉴定利用-1程序化核糖体移码的抗病毒药物的方法。 该方法包括提供含有-1帧质粒的细胞，其包含翻译起始位点，随后是-1个核糖体移码信号，随后是相对于翻译起始位点-1个帧的报道基因。 该方法还包括使细胞与测试试剂接触; 并在测试试剂存在下测定报道基因的活性，其中报道基因活性依赖于-1核糖体移码。